Monte Rosa Therapeutics Q2 collaboration revenue surges

Monte Rosa Therapeutics

07/08/2025 12:19

Overview

Monte Rosa Q2 collaboration revenue rises significantly, driven by Novartis partnership

Net loss for Q2 reduced compared to last year

Strong cash position expected to fund operations into 2028

Outlook

Company's cash position expected to fund operations into 2028

Result Drivers

NOVARTIS PARTNERSHIP - Collaboration revenue boosted by Novartis $150 mln upfront payment

R&D EXPENSES - Increased due to MRT-2359 study and QuEEN discovery engine development

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
$23.19 mln
Q2 Net Income
-$12.30 mln
Q2 Operating Expenses
$38.75 mln
Q2 Operating Income
-$15.55 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Monte Rosa Therapeutics Inc is $17.00, about 74.4% above its August 6 closing price of $4.36

Press Release: ID:nGNX87XFS3

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)